Data / Drug companies / Sunrise Pharmaceutical, Inc.
Sunrise Pharmaceutical, Inc.: 31 products in the FDA NDC directory, labeler code 11534
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sunrise Pharmaceutical, Inc. (labeler code 11534) lists 31 products in the FDA National Drug Code Directory, covering 12 finished drugs by generic name. By type: 30 prescription drugs, 1 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on December 11, 2025.
The request: Watch Sunrise Pharmaceutical, Inc. (FDA labeler code 11534): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 11534
- Products in commercial distribution
- 31
- Packages
- 71
- Finished drugs by generic name
- 12
- Prescription products
- 30
- Over the counter products
- 1
- Controlled substance products
- Schedule II 9, Schedule III 1, Schedule IV 8
- Flagged as original packager
- 31 of 31 products that carry the flag
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- August 4, 2015
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 31 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 30 | 96.8% |
| Over the counter drugs | 1 | 3.2% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 18 | 58.1% |
| Capsule | 5 | 16.1% |
| Tablet, delayed release | 3 | 9.7% |
| Tablet, film coated | 3 | 9.7% |
| Powder, for suspension | 1 | 3.2% |
| Powder, for solution | 1 | 3.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sulfasalazine | 11534-201 | Tablet, delayed release | Generic drugs (ANDA) | December 11, 2025 |
| Naproxen | 11534-212 | Tablet, delayed release | Generic drugs (ANDA) | December 9, 2025 |
| Naproxen | 11534-211 | Tablet, delayed release | Generic drugs (ANDA) | December 9, 2025 |
| Sulfasalazine | 11534-200 | Tablet | Generic drugs (ANDA) | July 15, 2025 |
| Diazepam | 11534-203 | Tablet | Generic drugs (ANDA) | December 9, 2024 |
| Diazepam | 11534-202 | Tablet | Generic drugs (ANDA) | December 9, 2024 |
| Diazepam | 11534-199 | Tablet | Generic drugs (ANDA) | December 9, 2024 |
| Benztropine mesylate | 11534-169 | Tablet | Generic drugs (ANDA) | October 16, 2024 |
| Benztropine mesylate | 11534-168 | Tablet | Generic drugs (ANDA) | October 16, 2024 |
| Benztropine mesylate | 11534-167 | Tablet | Generic drugs (ANDA) | October 16, 2024 |
| Hydroxyzine hydrochloride | 11534-205 | Tablet, film coated | Generic drugs (ANDA) | May 6, 2024 |
| Hydroxyzine hydrochloride | 11534-206 | Tablet, film coated | Generic drugs (ANDA) | May 1, 2024 |
| Hydroxyzine hydrochloride | 11534-204 | Tablet, film coated | Generic drugs (ANDA) | April 16, 2024 |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | 11534-197 | Capsule | Generic drugs (ANDA) | July 9, 2020 |
| Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate | 11534-196 | Tablet | Generic drugs (ANDA) | July 4, 2018 |
| Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate | 11534-195 | Tablet | Generic drugs (ANDA) | July 4, 2018 |
| Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate | 11534-194 | Tablet | Generic drugs (ANDA) | July 4, 2018 |
| Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate | 11534-193 | Tablet | Generic drugs (ANDA) | July 4, 2018 |
| Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate | 11534-192 | Tablet | Generic drugs (ANDA) | July 4, 2018 |
| Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate | 11534-191 | Tablet | Generic drugs (ANDA) | July 4, 2018 |
| Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate | 11534-190 | Tablet | Generic drugs (ANDA) | July 4, 2018 |
| Dextroamphetamine sulfate | 11534-189 | Tablet | Generic drugs (ANDA) | July 4, 2018 |
| Dextroamphetamine sulfate | 11534-188 | Tablet | Generic drugs (ANDA) | July 4, 2018 |
| Polyethylene glycol 3350 nf | 11534-180 | Powder, for solution | Generic drugs (ANDA) | June 13, 2017 |
| Phentermine Hydrochloride | 11534-176 | Capsule | Generic drugs (ANDA) | January 24, 2017 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.